Fortrea (FTRE) Stock Is Up, What You Need To Know

Fortrea Holdings (FTRE) agreed to buy the Early Phase Services division of Worldwide Clinical Trials, including labs and clinical units in Texas. The deal expands Fortrea's early development network, adding bioanalytical and clinical pharmacology capabilities. FTRE shares rose 5.98% to $18.78. According to the company, the acquisition supports growth and increases long-term shareholder value.

Fortrea (FTRE) will acquire Worldwide Clinical Trials' Early Phase Services division for $45M, including a bioanalytical lab and clinical pharmacology unit. The deal expands Fortrea's early clinical development capabilities, enhancing its platform for Phases I-IV studies. Worldwide will focus on its late-stage business. The transaction is subject to regulatory approvals.

Fortrea Holdings (FTRE) reported stronger biotech demand, a backlog of about $7.8B, and raised full-year 2026 revenue and adjusted EBITDA guidance, drawing renewed investor attention. Shares last closed at $18.43, up 4.18% on the day and 19.44% over 90 days. Simply Wall St cites a $17.25 fair value estimate and notes other valuation models.

"The environment has become more supportive, but our results are not simply the result of market recovery," Thakral said, attributing the performance to changes in commercial execution, including improved global coordination, a sharper focus on opportunities where the company can compete effectively and a clearer approach to serving distinct customer segments. Thakral said Fortrea's clinical pharmacology services business was a particular area of strength.

Fortrea Holdings (NASDAQ:FTRE) reported Q2 CY2026 revenue of $678.2 million, down 4.5% year over year but 4.7% above market expectations, according to the company. Full-year revenue guidance was $2.66 billion at the midpoint, 1.8% above analysts’ estimates. Non-GAAP EPS was $0.23, 27.2% above consensus.

Fortrea (Nasdaq: FTRE) reported Q2 2026 revenue of $678.2 million, down from $710.3 million a year earlier. GAAP net loss was $13.2 million, while adjusted net income was $22.7 million and adjusted EBITDA $58.7 million. Book-to-bill was 1.06x and backlog $7.8 billion. Full-year guidance was raised to $2.62B-$2.69B revenue and $205M-$220M adjusted EBITDA.